Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.

NCT00244127 is registered in ClinicalTrials.gov with Zeneus Pharma as lead sponsor.

NCT NCT00244127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00244127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.
Lead sponsor
Zeneus Pharma
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2002
Completion date
Not reported
Enrollment
75
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin's lymphoma in the elderly.